| Severe acute respiratory syndrome coronavirus 2− specific antibody responses in coronavirus disease patients NMA Okba, MA Müller, W Li, C Wang, CH GeurtsvanKessel, VM Corman, ... Emerging infectious diseases 26 (7), 1478, 2020 | 1337 | 2020 |
| Clinical and virological data of the first cases of COVID-19 in Europe: a case series FX Lescure, L Bouadma, D Nguyen, M Parisey, PH Wicky, S Behillil, ... The Lancet Infectious Diseases 20 (6), 697-706, 2020 | 1093 | 2020 |
| Evidence of sexual transmission of Zika virus E D’Ortenzio, S Matheron, X de Lamballerie, B Hubert, G Piorkowski, ... New England Journal of Medicine 374 (22), 2195-2198, 2016 | 735 | 2016 |
| Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy D Descamps, P Flandre, V Calvez, G Peytavin, V Meiffredy, G Collin, ... Jama 283 (2), 205-211, 2000 | 505 | 2000 |
| Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine-or efavirenz-based antiretroviral therapy JJ Parienti, V Massari, D Descamps, A Vabret, E Bouvet, B Larouzé, ... Clinical Infectious Diseases 38 (9), 1311-1316, 2004 | 307 | 2004 |
| Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial JL Meynard, M Vray, L Morand-Joubert, E Race, D Descamps, G Peytavin, ... Aids 16 (5), 727-736, 2002 | 297 | 2002 |
| Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient-and sequence-level meta-analysis SY Rhee, JL Blanco, MR Jordan, J Taylor, P Lemey, V Varghese, ... PLoS medicine 12 (4), e1001810, 2015 | 252 | 2015 |
| High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results … Y Yazdanpanah, C Fagard, D Descamps, AM Taburet, C Colin, ... Clinical Infectious Diseases 49 (9), 1441-1449, 2009 | 242 | 2009 |
| Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome V Descamps, F Bouscarat, S Laglenne, E Aslangul, B Veber, D Descamps, ... British Journal of Dermatology 137 (4), 605-608, 1997 | 235 | 1997 |
| Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses D Descamps, G Collin, F Letourneur, C Apetrei, F Damond, ... Journal of virology 71 (11), 8893-8898, 1997 | 231 | 1997 |
| SARS-CoV-2 specific antibody responses in COVID-19 patients NMA Okba, MA Müller, W Li, C Wang, CH GeurtsvanKessel, VM Corman, ... MedRxiv, 2020 | 214 | 2020 |
| Zika virus in the female genital tract N Prisant, L Bujan, H Benichou, PH Hayot, L Pavili, S Lurel, C Herrmann, ... The Lancet infectious diseases 16 (9), 1000-1001, 2016 | 207 | 2016 |
| Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C A Desnoyer, D Pospai, MP Lê, A Gervais, A Heurgué-Berlot, A Laradi, ... Journal of hepatology 65 (1), 40-47, 2016 | 186 | 2016 |
| A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations L Grzelak, S Temmam, C Planchais, C Demeret, L Tondeur, C Huon, ... Science translational medicine 12 (559), eabc3103, 2020 | 185 | 2020 |
| Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe LM Hofstra, N Sauvageot, J Albert, I Alexiev, F Garcia, D Struck, ... Clinical infectious diseases 62 (5), 655-663, 2016 | 162 | 2016 |
| Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy AJ Hance, V Lemiale, J Izopet, D Lecossier, V Joly, P Massip, ... Journal of virology 75 (14), 6410-6417, 2001 | 161 | 2001 |
| Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss E Dam, R Quercia, B Glass, D Descamps, O Launay, X Duval, ... PLoS pathogens 5 (3), e1000345, 2009 | 154 | 2009 |
| Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors D Descamps, C Apetrei, G Collin, F Damond, F Simon, F Brun-Vezinet Aids 12 (9), 1109-1111, 1998 | 153 | 1998 |
| Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma R Schuurman, D Descamps, GJ Weverling, S Kaye, J Tijnagel, I Williams, ... Journal of clinical microbiology 34 (12), 3016-3022, 1996 | 147 | 1996 |
| The Human Immunodeficiency Virus Type 2 Vpx Protein Usurps the CUL4A-DDB1DCAF1 Ubiquitin Ligase To Overcome a Postentry Block in Macrophage Infection A Bergamaschi, D Ayinde, A David, E Le Rouzic, M Morel, G Collin, ... Journal of virology 83 (10), 4854-4860, 2009 | 143 | 2009 |
